Biotech — India Patent Cases
102 decisions indexed
Page 4 of 4 · 102 total
M/S. Paam Biotech Pvt. Ltd. v.Registrar Of Trademarks, Govt. Of India
Paam Biotech Pvt. Ltd. filed a writ petition seeking an expeditious disposal of its long-pending trademark registration application for 'DELPAR.' The Rajasthan High Court intervened, directing the Registrar of Trademarks to process and decide the application no. 2192781 as quickly as possible, specifically within three months from receiving the court order. This ruling provides a crucial timeline for the petitioner's intellectual property rights.
Osaka University v.Assistant Controller Of Patents And Designs
Osaka University appealed the Patent Office's order rejecting its patent application (No. 3495/DELNP/2012) for 'Bridged Artificial Nucleoside and Nucleotide'. The rejection was based on lack of novelty, inventive step, and Section 3(d) of the Patents Act, 1970.
Bayer Pharma Aktiengesellschaft v.The Controller Of Patents
Bayer Pharma Aktiengesellschaft appealed an order by The Controller of Patents which rejected its patent application (No. 9149/DELNP/2014). The rejection was based on the grounds that the antibodies claimed were naturally occurring and thus non-patentable under Section 3(c) of the Act. The court allowed various interlocutory applications, including condonation of delay, and issued notice for further arguments.
The Regents of the University of California v.Controller General of Patents, Designs & Trademarks & Anr.
The Regents of the University of California filed an appeal challenging the rejection of their patent application, No.10336/DELNP/2013, titled "Blockade Of Inflammatory Proteases With Theta - Defensins." The initial rejections were based on objections under Section 2(1)(ja) and non-patentability under Section 3 of the Patents Act, 1970. After subsequent amendments, the application was rejected again under S. 59 r/w S.15. This order sets out procedural directions for the parties to file replies and written submissions before the next hearing.
Monsanto Holdings Private Limited v.Competition Commission Of India
This appeal challenges a single judge's decision that appellants (Monsanto) were governed by both the Competition Act, 2002, and the Patents Act, 1970. The core dispute revolves around whether competition law proceedings are applicable when patented seeds are involved. The court allowed several applications and issued an interim restraint on the CCI from finalizing its report pending further hearing.
Kanishk Sinha v.Union Of India
The Calcutta High Court disposed of the writ petitions filed by Kanishk Sinha against the Union of India. The court noted that the petitioner's patent application had been accepted online, substantially addressing his grievance.
Roche Products (India) Private Limited v.Cadila Healthcare Limited
The plaintiffs, including Roche Products and F. Hoffmann-La Roche, challenged the validity of drug approvals granted by the DCGI and DoB to Cadila Healthcare Ltd. for its biosimilar product 'Trastuzumab'. The core legal issue was whether the suit was maintainable given the regulatory framework, specifically concerning appeal provisions under the Drugs Rules.
Versalis Spa v.The Assistant Controller of Patents
Versalis Spa appealed the rejection of its patent application (IN7854/CHENP/2011) by the Assistant Controller. The core dispute was whether the process for hydrolyzing lignocellulosic biomass was inventive, given that the claims were challenged as lacking inventiveness and technical advancement over cited prior arts.
Merus N.V v.Assistant Controller of Patents and Designs, Government of India
Merus N.V appealed the rejection of its Indian Patent Application No. 467/CHENP/2011 by the Assistant Controller, which had been based on non-patentability grounds (Section 3(i) and 3(j)). The appellant argued that the amendments were permissible as they merely refined the claim to nucleic acid molecules while retaining the core invention. The High Court found merit in the appellant's argument regarding the scope of amendments.
Akb Jagannath Nag v.Union Of India & Ors.
Akb Jagannath Nag challenged an order from the Controllers of Patents and Designs. The appellant argued that subsequent approval under Section 6 of the Biological Diversity Act, 2002, should interfere with the impugned order. The court considered this new development but found it necessary for the appellant to approach the Single Judge for review or proceed via appeal.
Genentech Inc And Others v.Drugs Controller General Of India And Others
Genentech Inc. and its affiliates filed suit against the Drugs Controller General of India and others, challenging the approval granted for TrastuRel, a purported biosimilar version of their drug Trastuzumab. The plaintiffs contended that TrastuRel had not undergone adequate testing as required under Indian law before being launched. The Delhi High Court issued an interim order, restraining the defendant from marketing the product without proper trials while setting conditions for future regulatory approval.
Michigan State University v.The Assistant Controller Of Patents And ...
Michigan State University appealed the decision of the Patent Office to abandon its divisional patent application (No. 1699/DEL/1996). The Patent Office had maintained objections that the claimed expression cassette did not constitute an invention under Section 2(1)(j) and was non-patentable. The IPAB found the abandonment order unsustainable due to a violation of natural justice, as no opportunity of hearing was provided.
Dealing with a patent challenge?
Whether it's a Section 3(d) rejection, a post-grant opposition, or a FRAND dispute, Arctic's patent litigation team has handled it. Get a strategy call.